Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a (10)BSH-containing WOW emulsion.

• 影响指数: 1.787
• 发表时间: Jun 2014
• 来源期刊: Appl Radiat Isot
• DOI: 10.1016/j.apradiso.2014.01.014
• PMID: 24559940
• 文章类型: Case Reports
• 中科院分区: Q3
• 方向: 医学
• 作者列表: Yanagie H,Higashi S,Seguchi K,Ikushima I,Fujihara M,Nonaka Y,Oyama K,Maruyama S,Hatae R,Suzuki M,Masunaga S,Kinashi T,Sakurai Y,Tanaka H,Kondo N,Narabayashi M,Kajiyama T,Maruhashi A,Ono K,Nakajima J,Ono M,Takahashi H,Eriguchi M

关键词: Boron neutron capture therapy; Hepatocellular carcinoma; Intra-arterial injection; Water-in-oil-in-water emulsion

Mesh: Borohydrides / administration & dosage chemistry; Boron Neutron Capture Therapy / methods; Carcinoma, Hepatocellular / diagnosis radiotherapy; Emulsions / administration & dosage chemistry; Humans; Injections, Intra-Arterial; Liver Neoplasms / diagnosis radiotherapy; Male; Middle Aged; Neoplasm Recurrence, Local / diagnosis radiotherapy; Oils / chemistry; Pilot Projects; Sulfhydryl Compounds / administration & dosage chemistry; Treatment Outcome; Water / chemistry

Abstract

A 63-year-old man with multiple HCC in his left liver lobe was enrolled as the first patient in a pilot study of boron neutron capture therapy (BNCT) involving the selective intra-arterial infusion of a (10)BSH-containing water-in-oil-in-water emulsion ((10)BSH-WOW). The size of the tumorous region remained stable during the 3 months after the BNCT. No adverse effects of the BNCT were observed. The present results show that (10)BSH-WOW can be used as novel intra-arterial boron carriers during BNCT for HCC.